ATE488583T1 - Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält - Google Patents

Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält

Info

Publication number
ATE488583T1
ATE488583T1 AT02716799T AT02716799T ATE488583T1 AT E488583 T1 ATE488583 T1 AT E488583T1 AT 02716799 T AT02716799 T AT 02716799T AT 02716799 T AT02716799 T AT 02716799T AT E488583 T1 ATE488583 T1 AT E488583T1
Authority
AT
Austria
Prior art keywords
hcmv
clinical isolate
virus
vector containing
recombinant vector
Prior art date
Application number
AT02716799T
Other languages
English (en)
Inventor
Gabriele Hahn
Original Assignee
Wistar Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Inst filed Critical Wistar Inst
Application granted granted Critical
Publication of ATE488583T1 publication Critical patent/ATE488583T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/245Herpetoviridae, e.g. herpes simplex virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16132Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16111Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16161Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT02716799T 2001-02-21 2002-02-21 Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält ATE488583T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01104171 2001-02-21
EP01116044 2001-07-02
PCT/EP2002/001867 WO2002066629A2 (en) 2001-02-21 2002-02-21 Recombinant vector containing infectious human cytomegalovirus genome with preserved wild-type characteristics of clinical isolates

Publications (1)

Publication Number Publication Date
ATE488583T1 true ATE488583T1 (de) 2010-12-15

Family

ID=26076487

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02716799T ATE488583T1 (de) 2001-02-21 2002-02-21 Rekombinant vektor, der ein infektiöses humanes cytomegalovirus genom mit konserviertem wildtyp- charakteristika klinisher isolate enthält

Country Status (7)

Country Link
US (3) US20040087001A1 (de)
EP (1) EP1368465B1 (de)
AT (1) ATE488583T1 (de)
AU (1) AU2002247733B2 (de)
CA (1) CA2438322A1 (de)
DE (1) DE60238309D1 (de)
WO (1) WO2002066629A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2654563A1 (en) 2006-06-07 2007-12-21 The Trustees Of Princeton University Cytomegalovirus surface protein complex for use in vaccines and as a drug target
EP3399025B1 (de) * 2007-03-23 2025-05-07 Wisconsin Alumni Research Foundation Neuprogrammierung von körperzellen
PT3009449T (pt) 2008-07-16 2018-09-28 Inst Res Biomedicine Anticorpos neutralizantes de citomegalovírus humano e utilização destes
EA201270662A1 (ru) 2009-12-23 2013-01-30 4-Антибоди Аг Связывающие элементы для человеческого цитамегаловируса
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP3333265B1 (de) 2010-05-14 2020-02-05 Oregon Health & Science University Rekombinante hcmv- und rhcmv-vektoren die ein heterologes antigen aus dem hepatitis b virus kodieren und deren verwendungen
SMT201800284T1 (it) 2011-06-10 2018-07-17 Univ Oregon Health & Science Glicoproteine cmv e vettori ricombinanti
EP2766385A2 (de) * 2011-10-12 2014-08-20 Novartis AG Cmv-antigene und verwendungen davon
SI2964769T1 (sl) * 2013-03-05 2018-12-31 Oregon Health & Sccience University Citomegalovirusni vektorji, ki omogočajo krmiljenje ciljanja T-celic
KR102205348B1 (ko) 2014-07-16 2021-01-20 오레곤 헬스 앤드 사이언스 유니버시티 외인성 항원을 포함하는 인간 시토메갈로바이러스
CN114317611A (zh) 2015-02-10 2022-04-12 俄勒冈健康与科学大学 可用于产生非典型cd8+t细胞应答的方法和组合物
AU2016355468B2 (en) * 2015-11-20 2022-12-15 Oregon Health & Science University CMV vectors comprising microRNA recognition elements
US10611800B2 (en) 2016-03-11 2020-04-07 Pfizer Inc. Human cytomegalovirus gB polypeptide
US20200182884A1 (en) 2016-06-27 2020-06-11 Juno Therapeutics, Inc. Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
CN110036112B (zh) 2016-10-18 2024-05-10 俄勒冈健康与科学大学 引发受主要组织相容性复合体e分子限制的t细胞的巨细胞病毒载体
US10577763B2 (en) * 2017-04-25 2020-03-03 MZC Foundation, Inc. Apparatus, system, and method for smart roadway stud control and signaling
US11629172B2 (en) 2018-12-21 2023-04-18 Pfizer Inc. Human cytomegalovirus gB polypeptide
US11857622B2 (en) 2020-06-21 2024-01-02 Pfizer Inc. Human cytomegalovirus GB polypeptide

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19733364A1 (de) * 1997-08-01 1999-02-04 Koszinowski Ulrich H Prof Verfahren zur Klonierung eines großen Virusgenoms

Also Published As

Publication number Publication date
US7700350B2 (en) 2010-04-20
WO2002066629A8 (en) 2003-02-27
AU2002247733B2 (en) 2007-12-13
CA2438322A1 (en) 2002-08-29
DE60238309D1 (de) 2010-12-30
US20100267121A1 (en) 2010-10-21
WO2002066629A3 (en) 2003-10-09
US20060019369A1 (en) 2006-01-26
EP1368465B1 (de) 2010-11-17
US20040087001A1 (en) 2004-05-06
EP1368465A2 (de) 2003-12-10
WO2002066629A2 (en) 2002-08-29
WO2002066629A9 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
DE60238309D1 (de) Tomegalovirus genom mit konserviertem wildtyp-charakteristika klinisher isolate enthält
Crawford-Miksza et al. Adenovirus serotype evolution is driven by illegitimate recombination in the hypervariable regions of the hexon protein
Ciota et al. Role of the mutant spectrum in adaptation and replication of West Nile virus
Novella et al. Lack of evolutionary stasis during alternating replication of an arbovirus in insect and mammalian cells
DK1554301T3 (da) Dengue-vaccine med en fælles udeladelse af 30 nukleotider i Dengue-typerne 1's og 2's3'UTR
Gaunt et al. Compositional biases in RNA viruses: Causes, consequences and applications
ATE130870T1 (de) Von adeno-assoziierte viren rekombinante vektoren.
WO2005014806A3 (en) Conserved hbv and hcv sequences useful for gene silencing
MY117686A (en) Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof
HUP0203305A2 (hu) Fertőző klónok
MX9801715A (es) Secuencia novedosa en el extremo 3' del genoma del virus de la hepatitis c, y su uso en diagnostico y en la preparacion de composiciones terapeuticas.
CN102210861A (zh) 丙型肝炎病毒多表位肽负荷的树突状细胞治疗性疫苗
TR200002909T2 (tr) Rekombinant potivirüs yapısı ve kullanımı
HUP0401585A2 (hu) Fertőző, marhában előforduló, vírusos hasmenés vírusklónja
DK1356062T3 (da) Frembringelse af rekombinanter af kunstigt gærkromosom af human cytomegalovirus
Esteban-Riesco et al. Rapid and sustained autologous neutralizing response leading to early spontaneous recovery after HCV infection
Kobayashi et al. Requirement of cauliflower mosaic virus open reading frame VI product for viral gene expression and multiplication in turnip protoplasts
WO1999057284A3 (en) Attenuated influenza viruses
Park et al. Efficiency of reverse genetics methods for rescuing severe acute respiratory syndrome coronavirus 2
Keyer et al. Towards development of plasmacytoma cells-based expression systems utilizing alphavirus vectors: An NS0-VEE model
JP2011092196A5 (de)
Bosch et al. Coding biases and viral fitness
CN113862287B (zh) 一种3a型丙型肝炎病毒全长感染性克隆突变体及其应用
ES2125842A1 (es) Clones y vectores infectivos de plantas derivados del virus del mosaico del nabo (tumv).
Balol et al. Sources of genetic variation in plant virus populations

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties